Jiang Wen G, Martin Tracey A, Parr Christian, Davies Gaynor, Matsumoto Kunio, Nakamura Toshikazu
Metastasis and Angiogenesis Research Group, University Department of Surgery, Wales College of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
Crit Rev Oncol Hematol. 2005 Jan;53(1):35-69. doi: 10.1016/j.critrevonc.2004.09.004.
Hepatocyte growth factor plays multiple roles in cancer, by acting as a motility and invasion stimulating factor, promoting metastasis and tumour growth. Furthermore, it acts as a powerful angiogenic factor. The pivotal role of this factor in cancer has indicated HGF as being a potential target in cancer therapies. The past few years have seen rapid progress in developing tools in targeting HGF, in the context of cancer therapies, including development of antagonists, small compounds, antibodies and genetic approaches. The current article discusses the potential value of HGF and its receptor as targets in cancer therapies, the current development in anti-HGF research, and the clinical value of HGF in prognosis and treatment.
肝细胞生长因子在癌症中发挥多种作用,它作为一种刺激运动和侵袭的因子,促进转移和肿瘤生长。此外,它还是一种强大的血管生成因子。该因子在癌症中的关键作用表明肝细胞生长因子是癌症治疗中的一个潜在靶点。在癌症治疗背景下,过去几年在开发靶向肝细胞生长因子的工具方面取得了快速进展,包括拮抗剂、小分子化合物、抗体和基因方法的开发。本文讨论了肝细胞生长因子及其受体作为癌症治疗靶点的潜在价值、抗肝细胞生长因子研究的当前进展以及肝细胞生长因子在预后和治疗中的临床价值。